Results 71 to 80 of about 21,294 (218)

CRISPR Enabled Precision Oncology: From Gene Editing to Tumor Microenvironment Remodeling

Med Research, EarlyView.
CRISPR technology has progressed from a prokaryotic immune system to a diverse suite of editing platforms, including Cas nucleases, base and prime editors, and RNA‐targeting enzymes. These advances enable precise genomic and epigenomic interventions, high‐throughput functional screening, and immune engineering.
Kailai Li, Peixin Huang, Yue Qian, Anqi Lin, Jingjun He, Junyi Shen, Li Chen, Kai Miao, Jian Zhang   +8 more
wiley   +1 more source

A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation. [PDF]

, 2014
Although anaplastic large-cell lymphomas (ALCL) carrying anaplastic lymphoma kinase (ALK) have a relatively good prognosis, aggressive forms exist. We have identified a novel translocation, causing the fusion of the TRAF1 and ALK genes, in one patient ...
...], Abate, F., Abele, C., Acquaviva, A., Agostinelli, C., Aime, S., Aliberti, S., Barreca, A., Bertoni, F., Bessone, L., Boi, M., Cerchietti, L., Chan, W.C., Cheng, M., Crescenzo, R., Di Giacomo, F., Falini, B., Ficarra, E., Gaudiano, M., Inghirami, G., Iqbal, J., Kwee, I., Landra, I., Lasorsa, E., Longo, D.L., Machiorlatti, R., Messana, K., Novero, D., Pera-Gresely, B., Piccaluga, P.P., Pileri, S., Piva, R., Ponzoni, M., Rabadan, R., Rinaldi, A., Ruggeri, B., Shultz, L.D., Tabb\uf2, F., The European T-cell Lymphoma Study Group [..., Tiacci, E., Todaro, M., Tousseyn, T., Van Der Krogt, J.-A., Wlodarska, I.   +43 more
core   +1 more source

Real‐world data on EGFR/ALK gene status and first‐line targeted therapy rate in newly diagnosed advanced non‐small cell lung cancer patients in Northern China: A prospective observational study

Thoracic Cancer, 2019
Background Tyrosine kinase inhibitors (TKIs) can significantly prolong overall survival for patients with advanced non‐small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR)‐mutation or anaplastic lymphoma kinase (ALK ...
Hongge Liang, Xia Song, Yuhui Zhang, Shucai Zhang, Fang Li, Jian Fang, Junling Li, Li Liang, Ligong Nie, Kewei Ma, Liangming Zhang, Xiaohong Wang, Junjun Xu, Yanxia Wei, Jinghui Wang, Qi Song, Guangming Tian, Yuxin Mu, Yangchun Gu, Lei Yang, Ping Sun, Wei Zhong, Jing Zhao, Yan Xu, Minjiang Chen, Mengzhao Wang   +25 more
doaj   +1 more source

Cytomorphological features of lung adenocarcinoma with anaplastic lymphoma kinase gene rearrangement

Journal of Cytology, 2019
Background: The anaplastic lymphoma kinase (ALK) gene rearrangement is a predictive and prognostic marker in pulmonary adenocarcinoma. A series of clinical and pathological features have been documented in patients who harbor this translocation.
Saumya Shukla, Nuzhat Husain, Anurag Gupta, Nidhi Anand   +3 more
doaj   +1 more source

Case Report: Treatment of Alectinib in NSCLC With Brain Metastasis Patient Refractory to Radiotherapy After Resistance to Crizotinib

Frontiers in Oncology, 2021
BackgroundBrain metastasis is the most common form of tumor recurrence after resistance to crizotinib in patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC).
Chunzhi Zhang
doaj   +1 more source

Computational Evaluation of Statin Analogs Targeting HMG‐CoA Reductase for Coronary Artery Disease Treatment

ChemistryOpen, EarlyView.
Molecular dynamics analysis of novel statin analogs shows that binding induces superior stabilization of HMG‐CoA reductase. As shown by the solvent‐accessible surface area profile, ligand‐induced rigidity offers a new, effective strategy for drug design. Cardiovascular diseases remain a leading cause of global mortality.
Yoshua B. Mtulo, Geradius Deogratias, James E. Mgaya, Andrew S. Paluch, Lucas Paul   +4 more
wiley   +1 more source

Aberrant expression of ALK and EZH2 in Merkel cell carcinoma [PDF]

, 2017
BACKGROUND: Distinct characteristic features categorize Merkel cell carcinoma (MCC) into two subgroups according to the Merkel cell polyomavirus infection.
Bohling, T., Kero, M., Knuutila, S., Koljonen, V., Sarhadi, Virinder Kaur, Veija, T.   +5 more
core   +1 more source

ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer [PDF]

JNCI: Journal of the National Cancer Institute, 2017
ALK, ROS1, and NTRK fusions occur in 0.2% to 2.4% of colorectal cancers. Pioneer cases of metastatic colorectal cancer (mCRC) patients bearing rearrangements who benefited from anti-ALK, ROS, and TrkA-B-C therapies have been reported previously. Here we aimed at characterizing the clinical and molecular landscape of ALK, ROS1, and NTRK rearranged mCRC ...
F. Pietrantonio, F. Di Nicolantonio, A. B. Schrock, J. Lee, S. Tejpar, A. Sartore-Bianchi, J. F. Hechtman, J. Christiansen, L. Novara, N. Tebbutt, G. Fucà, C. Antoniotti, S. T. Kim, D. Murphy, R. Berenato, F. Morano, J. Sun, B. Min, P. J. Stephens, M. Chen, L. Lazzari, V. A. Miller, R. Shoemaker, A. Amatu, M. Milione, J. S. Ross, S. Siena, A. Bardelli, S. M. Ali, A. Falcone, F. de Braud, C. Cremolini   +31 more
openaire   +4 more sources

Ashwagandha: Is It Safe? Part 2: A Preclinical Evidence Review

Phytotherapy Research, EarlyView.
ABSTRACT The preclinical evidence for the safety of ashwagandha (Withania somnifera (L.) Dunal, AS) is reviewed, and its preparations (extracts) and constituents, from the general toxicity in animal models to in vitro and cell culture studies, which may elucidate mechanisms of action and explain clinical case reports.
Elizabeth M. Williamson, Thomas Brendler
wiley   +1 more source

Accurate Identification of ALK Positive Lung Carcinoma Patients: Novel FDA-Cleared Automated Fluorescence In Situ Hybridization Scanning System and Ultrasensitive Immunohistochemistry

, 2017
Background: Based on the excellent results of the clinical trials with ALK-inhibitors, the importance of accurately identifying ALK positive lung cancer has never been greater.
Abdulkader, Ihab, Arriola Aperribay, Edurne, Benito, Amparo, Biscuola, Michele, Camacho, María del Carmen, Castro, Javier de, Conde, Esther, Folgueras, Victoria, García Campelo, Rosario, Garrido, Pilar, Gómez Román, Javier, Hardisson, David, Hidalgo, Manuel, López Ríos, Fernando, Paz-Ares, Luis, Pijuan, Lara, Ramírez Ruz, J. (José), Reguart, Noemí, Rodríguez Abreu, Delvys, Salido Galeote, Marta, Sanz, Julián, Suárez Gauthier, Ana, Villanueva, Noemí   +22 more
core   +1 more source